Asymmetrical Dimethylarginine (ADMA) CLIA Kit

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Asymmetrical Dimethylarginine (ADMA) Chemiluminescent Immunoassay (CLIA) Kit is a Competitive Chemiluminescent Immunoassay (CLIA) Kit for use with Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.
Documents del producto
Product specifications
Category | CLIA Kits |
Immunogen Target | Asymmetrical Dimethylarginine (ADMA) |
Reactivity | General |
Detection Method | Chemiluminescent |
Assay Data | Quantitative |
Assay Type | Competitive |
Test Range | 3.9 ng/ml - 1000 ng/ml |
Sensitivity | < 1.5 ng/ml |
Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
Size 1 | 96 tests |
Size 2 | 5 × 96 tests |
Size 3 | 10 × 96 tests |
Form | Lyophilized |
Tested Applications | CLIA |
Sample Type | Serum, plasma, tissue homogenates, cell lysates, cell culture supernatants and other biological fluids. |
Availability | Shipped within 5-20 working days. |
Storage | Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual. |
Dry Ice | No |
Alias | ADMA |
Background | CLIA Kits ADMA |
Status | RUO |
Note | The validity for this kit is at least 6 months. Up to 12 months validity can be provided on request. This product is for research use only. The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments. Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein. |
Descripción
Asymmetrical dimethylarginine (ADMA) is an endogenous molecule that competitively inhibits nitric oxide synthase (NOS), thereby reducing nitric oxide (NO) production and impairing vascular tone, endothelial function, and blood flow. As a key regulator of NO bioavailability, ADMA is a critical factor in cardiovascular health. Elevated ADMA levels are associated with endothelial dysfunction, hypertension, atherosclerosis, and heart failure, as insufficient NO contributes to inflammation, vascular rigidity, and oxidative stress. ADMA is metabolized by dimethylarginine dimethylaminohydrolase (DDAH), and any imbalance between ADMA production and clearance affects vascular and metabolic health. Beyond cardiovascular diseases, ADMA dysregulation is linked to chronic kidney disease, diabetes, and neurodegenerative disorders. ADMA serves as a biomarker for assessing cardiovascular and metabolic risks, and targeting the DDAH-ADMA-NO pathway is an emerging strategy to restore endothelial health and reduce vascular inflammation.
Related Products

Asymmetrical Dimethylarginine (ADMA) Antibody
Polyclonal Antibody to Asymmetrical Dimethylarginine (ADMA).
Ver Producto
Asymmetrical Dimethylarginine (ADMA) ELISA Kit
Asymmetrical Dimethylarginine (ADMA) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Asymmetrical Dimethylarginine (ADMA) concentrations in serum, plasma, tissue homogenates, cell lysates, cell culture supernatants and other biological fluids. This assay has high sensitivity and excellent specificity for detection of Asymmetrical Dimethylarginine (ADMA)
Ver Producto
Asymmetrical Dimethylarginine (ADMA) ELISA Kit
Asymmetrical Dimethylarginine (ADMA) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Asymmetrical Dimethylarginine (ADMA) concentrations in serum, plasma, tissue homogenates, cell lysates, cell culture supernatant and other biological fluids.
Ver Producto